search
Back to results

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Primary Purpose

Atopic Dermatitis

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Tralokinumab
Sponsored by
LEO Pharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atopic Dermatitis

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Completed the treatment period(s) of one of the parent trials: LP0162-1325, -1326, -1334, -1339, -1341, -1342, -1343, -1346, or TRA-WEI-0015-I.
  • Complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator.
  • Able and willing to self-administer tralokinumab treatment (or have it administered by a caregiver) at home after the initial 3 injection visits at the trial site (in this trial).
  • Stable dose of emollient twice daily (or more, as needed) for at least 14 days before baseline.

Exclusion Criteria:

  • Any condition that required permanent discontinuation of trial treatment in the parent trial.
  • More than 26 weeks have elapsed since the subject received the last injection of investigational medicinal product (IMP) in the parent trial (to be assessed at baseline).
  • Subjects who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to tralokinumab by the investigator, which in the opinion of the investigator could indicate that continued treatment with tralokinumab may present an unreasonable safety risk for the subject.
  • Subjects who, during their participation in the parent trial, developed an AE that was deemed related to tralokinumab by the investigator and led to temporary discontinuation of trial treatment, which in the opinion of the investigator could indicate that continued treatment with tralokinumab may present an unreasonable safety risk for the subject.
  • Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to baseline.
  • Treatment with topical phosphodiesterase 4 inhibitors or topical JAK inhibitors within 2 weeks prior to baseline.
  • Clinically significant infection within 4 weeks prior to baseline.
  • A helminth parasitic infection within 6 months prior to the date when informed consent is obtained.
  • Tuberculosis requiring treatment within 12 months prior to screening.
  • Known primary immunodeficiency disorder.

Sites / Locations

  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site 1
  • LEO Pharma Investigational Site 2
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site 2
  • LEO Pharma Investigational Site 1
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site
  • LEO Pharma Investigational Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Tralokinumab, all subjects

Arm Description

Week 0: subcutaneous (SC) injection of tralokinumab loading dose. From Week 2 up to Week 266*: SC injection of tralokinumab maintenance dose. *The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from.

Outcomes

Primary Outcome Measures

Number of adverse events from baseline through the last treatment visit (up to Week 268)

Secondary Outcome Measures

Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Weeks 16, 56, 88, 104, 136, 152, 184, 216, and 248
The IGA is an instrument used in clinical trials to rate the severity of the subject's global atopic dermatitis and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
At least 75% reduction in Eczema Area and Severity Index (EASI75) relative to baseline in parent trial, at Weeks 16, 56, 88, 104, 136, 152, 184, 216, and 248
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.

Full Information

First Posted
July 3, 2018
Last Updated
August 9, 2023
Sponsor
LEO Pharma
search

1. Study Identification

Unique Protocol Identification Number
NCT03587805
Brief Title
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
Official Title
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 18, 2018 (Actual)
Primary Completion Date
June 14, 2024 (Anticipated)
Study Completion Date
July 5, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LEO Pharma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1672 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tralokinumab, all subjects
Arm Type
Experimental
Arm Description
Week 0: subcutaneous (SC) injection of tralokinumab loading dose. From Week 2 up to Week 266*: SC injection of tralokinumab maintenance dose. *The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from.
Intervention Type
Drug
Intervention Name(s)
Tralokinumab
Intervention Description
Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
Primary Outcome Measure Information:
Title
Number of adverse events from baseline through the last treatment visit (up to Week 268)
Time Frame
From Week 0 up to Week 268
Secondary Outcome Measure Information:
Title
Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Weeks 16, 56, 88, 104, 136, 152, 184, 216, and 248
Description
The IGA is an instrument used in clinical trials to rate the severity of the subject's global atopic dermatitis and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
Time Frame
From Week 16 up to Week 248
Title
At least 75% reduction in Eczema Area and Severity Index (EASI75) relative to baseline in parent trial, at Weeks 16, 56, 88, 104, 136, 152, 184, 216, and 248
Description
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.
Time Frame
From Week 16 up to Week 248

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Completed the treatment period(s) of one of the parent trials: LP0162-1325, -1326, -1334, -1339, -1341, -1342, -1343, -1346, or TRA-WEI-0015-I. Complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator. Able and willing to self-administer tralokinumab treatment (or have it administered by a caregiver) at home after the initial 3 injection visits at the trial site (in this trial). Stable dose of emollient twice daily (or more, as needed) for at least 14 days before baseline. Exclusion Criteria: Any condition that required permanent discontinuation of trial treatment in the parent trial. More than 26 weeks have elapsed since the subject received the last injection of investigational medicinal product (IMP) in the parent trial (to be assessed at baseline). Subjects who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to tralokinumab by the investigator, which in the opinion of the investigator could indicate that continued treatment with tralokinumab may present an unreasonable safety risk for the subject. Subjects who, during their participation in the parent trial, developed an AE that was deemed related to tralokinumab by the investigator and led to temporary discontinuation of trial treatment, which in the opinion of the investigator could indicate that continued treatment with tralokinumab may present an unreasonable safety risk for the subject. Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to baseline. Treatment with topical phosphodiesterase 4 inhibitors or topical JAK inhibitors within 2 weeks prior to baseline. Clinically significant infection within 4 weeks prior to baseline. A helminth parasitic infection within 6 months prior to the date when informed consent is obtained. Tuberculosis requiring treatment within 12 months prior to screening. Known primary immunodeficiency disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical expert
Organizational Affiliation
LEO Pharma
Official's Role
Study Director
Facility Information:
Facility Name
LEO Pharma Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35233
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36695
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Fort Smith
State/Province
Arkansas
ZIP/Postal Code
72916
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Bakersfield
State/Province
California
ZIP/Postal Code
93301
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90212
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90045
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92660
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Diego
State/Province
California
ZIP/Postal Code
92119
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Francisco
State/Province
California
ZIP/Postal Code
94132
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93405
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Santa Ana
State/Province
California
ZIP/Postal Code
92701
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
LEO Pharma Investigational Site
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Doral
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33015
Country
United States
Facility Name
LEO Pharma Investigational Site 1
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
LEO Pharma Investigational Site 2
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
LEO Pharma Investigational Site
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Orange Park
State/Province
Florida
ZIP/Postal Code
32073
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Sweetwater
State/Province
Florida
ZIP/Postal Code
33172
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33614
Country
United States
Facility Name
LEO Pharma Investigational Site
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
LEO Pharma Investigational Site
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33406
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Albany
State/Province
Georgia
ZIP/Postal Code
31707
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31217
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Newnan
State/Province
Georgia
ZIP/Postal Code
30263
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Clarksville
State/Province
Indiana
ZIP/Postal Code
47129
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Plainfield
State/Province
Indiana
ZIP/Postal Code
46168
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66215
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40215
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40217
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70601
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Bangor
State/Province
Maine
ZIP/Postal Code
04401
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Brighton
State/Province
Massachusetts
ZIP/Postal Code
02135
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Quincy
State/Province
Massachusetts
ZIP/Postal Code
02169
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48103
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Troy
State/Province
Michigan
ZIP/Postal Code
48084
Country
United States
Facility Name
LEO Pharma Investigational Site
City
West Bloomfield
State/Province
Michigan
ZIP/Postal Code
48322
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Saint Joseph
State/Province
Missouri
ZIP/Postal Code
64506
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Missoula
State/Province
Montana
ZIP/Postal Code
59808
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89074
Country
United States
Facility Name
LEO Pharma Investigational Site
City
East Windsor
State/Province
New Jersey
ZIP/Postal Code
08520
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Cortland
State/Province
New York
ZIP/Postal Code
13045
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Horseheads
State/Province
New York
ZIP/Postal Code
14845
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Kew Gardens
State/Province
New York
ZIP/Postal Code
11415
Country
United States
Facility Name
LEO Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
LEO Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Facility Name
LEO Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States
Facility Name
LEO Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27612
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Bexley
State/Province
Ohio
ZIP/Postal Code
43209
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45231
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Dublin
State/Province
Ohio
ZIP/Postal Code
43016
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Fairborn
State/Province
Ohio
ZIP/Postal Code
45324
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43617
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97223
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
LEO Pharma Investigational Site
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29420
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Goodlettsville
State/Province
Tennessee
ZIP/Postal Code
37072
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75225
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Frisco
State/Province
Texas
ZIP/Postal Code
75034
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Pflugerville
State/Province
Texas
ZIP/Postal Code
78660
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
LEO Pharma Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78218
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Facility Name
LEO Pharma Investigational Site
City
South Burlington
State/Province
Vermont
ZIP/Postal Code
05403
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26505
Country
United States
Facility Name
LEO Pharma Investigational Site
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Brussel
ZIP/Postal Code
1090
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Gent
ZIP/Postal Code
B-9000
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Herstal
ZIP/Postal Code
B-4040
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Liège
ZIP/Postal Code
4000 LIEGE
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Loverval
ZIP/Postal Code
6280
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Maldegem
ZIP/Postal Code
9990
Country
Belgium
Facility Name
LEO Pharma Investigational Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2J 7E1
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T3E 0B2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T5K 1X3
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1C3
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3R 6A7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V 0C6
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E8
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6H 4E1
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3C 0N2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3M 3Z4
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Bathurst
State/Province
New Brunswick
ZIP/Postal Code
E2A 4Z9
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Fredericton
State/Province
New Brunswick
ZIP/Postal Code
E3B 1G9
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Saint John's
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1A 4Y3
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1Z2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Ajax
State/Province
Ontario
ZIP/Postal Code
L1S 7K8
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Etobicoke
State/Province
Ontario
ZIP/Postal Code
M8X 1Y9
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8S 1G5
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 3H7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6H 5L5
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 1X3
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5H 1G9
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
North Bay
State/Province
Ontario
ZIP/Postal Code
P1B 3Z7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Oakville
State/Province
Ontario
ZIP/Postal Code
L6J 7W5
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K2C 3N2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Peterborough
State/Province
Ontario
ZIP/Postal Code
K9J 5K2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Richmond Hill
State/Province
Ontario
ZIP/Postal Code
L4B 1A5
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Richmond Hill
State/Province
Ontario
ZIP/Postal Code
L4C 9M7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3B 3S6
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4W 2N2
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5A 3R6
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Waterloo
State/Province
Ontario
ZIP/Postal Code
N2J 1C4
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N8W 1E6
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Windsor
State/Province
Ontario
ZIP/Postal Code
N8X 2G1
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3H 1V4
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1V 4X7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Verdun
State/Province
Quebec
ZIP/Postal Code
H4G 3E7
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7K 0H6
Country
Canada
Facility Name
LEO Pharma Investigational Site
City
Karlovy Vary
ZIP/Postal Code
360 01
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Kutná Hora
ZIP/Postal Code
284 01
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Ostrava-Poruba
ZIP/Postal Code
708 52
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Pardubice
ZIP/Postal Code
530 02
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Prague
ZIP/Postal Code
100 00
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Prague
ZIP/Postal Code
110 00
Country
Czechia
Facility Name
LEO Pharma Investigational Site
City
Marseille
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13285
Country
France
Facility Name
LEO Pharma Investigational Site
City
Bordeaux
ZIP/Postal Code
33 075
Country
France
Facility Name
LEO Pharma Investigational Site
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
LEO Pharma Investigational Site
City
Grenoble
ZIP/Postal Code
38000
Country
France
Facility Name
LEO Pharma Investigational Site
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Name
LEO Pharma Investigational Site
City
Martigues
ZIP/Postal Code
13500
Country
France
Facility Name
LEO Pharma Investigational Site
City
Mulhouse
ZIP/Postal Code
68100
Country
France
Facility Name
LEO Pharma Investigational Site
City
Nice
ZIP/Postal Code
06202
Country
France
Facility Name
LEO Pharma Investigational Site
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
LEO Pharma Investigational Site
City
Pierre-Bénite
ZIP/Postal Code
69495
Country
France
Facility Name
LEO Pharma Investigational Site
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
LEO Pharma Investigational Site
City
Saint-Étienne
ZIP/Postal Code
42000
Country
France
Facility Name
LEO Pharma Investigational Site
City
Toulouse
ZIP/Postal Code
31000
Country
France
Facility Name
LEO Pharma Investigational Site
City
Valence
ZIP/Postal Code
26000
Country
France
Facility Name
LEO Pharma Investigational Site
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Augsburg
ZIP/Postal Code
86179
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Bad Bentheim
ZIP/Postal Code
48455
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Berlin
ZIP/Postal Code
10789
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Bielefeld
ZIP/Postal Code
33647
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Bochum
ZIP/Postal Code
44793
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Darmstadt
ZIP/Postal Code
64283
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Dülmen
ZIP/Postal Code
48249
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Frankfurt am Main
ZIP/Postal Code
60590
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Friedrichshafen
ZIP/Postal Code
88045
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Gera
ZIP/Postal Code
07548
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Halle
ZIP/Postal Code
06097
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Hamburg
ZIP/Postal Code
20537
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Hamburg
ZIP/Postal Code
22391
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Hanover
ZIP/Postal Code
30159
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Jena
ZIP/Postal Code
07743
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Mainz
ZIP/Postal Code
55128
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
München
ZIP/Postal Code
80337
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Osnabrück
ZIP/Postal Code
49074
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Selters
ZIP/Postal Code
56242
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
LEO Pharma Investigational Site
City
Brescia
ZIP/Postal Code
25123
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
Catania
ZIP/Postal Code
95123
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
L'Aquila
ZIP/Postal Code
67100
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
Roma
ZIP/Postal Code
00144
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
Roma
ZIP/Postal Code
00168
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
Rozzano
ZIP/Postal Code
20089
Country
Italy
Facility Name
LEO Pharma Investigational Site
City
Ichikawa-shi
State/Province
Chiba
ZIP/Postal Code
272-0033
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Ichikawa-shi
State/Province
Chiba
ZIP/Postal Code
272-0143
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Chikushino-shi
State/Province
Fukuoka
ZIP/Postal Code
818-0083
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Fukuoka-shi
State/Province
Fukuoka
ZIP/Postal Code
814-0171
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Asahikawa
State/Province
Hokkaido
ZIP/Postal Code
070-8610
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Sapporo-shi
State/Province
Hokkaido
ZIP/Postal Code
060-0807
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Sapporo-shi
State/Province
Hokkaido
ZIP/Postal Code
063-0812
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Nonoichi-shi
State/Province
Ishikawa
ZIP/Postal Code
921-8801
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Kagoshima-shi
State/Province
Kagoshima
ZIP/Postal Code
890-0063
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Kawasaki-shi
State/Province
Kanagawa
ZIP/Postal Code
211-0063
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Yokohama-shi
State/Province
Kanagawa
ZIP/Postal Code
220-6208
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Yokohama-shi
State/Province
Kanagawa
ZIP/Postal Code
221-0825
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Toyonaka-shi
State/Province
Osaka
ZIP/Postal Code
560-0085
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Koto-Ku
State/Province
Tokyo
ZIP/Postal Code
136-0074
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Minato-Ku
State/Province
Tokyo
ZIP/Postal Code
108-0014
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Setagaya-ku
State/Province
Tokyo
ZIP/Postal Code
158-0097
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Shinjuku-Ku
State/Province
Tokyo
ZIP/Postal Code
169-0075
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Chuo Ku
ZIP/Postal Code
060-0033
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Chuo Ku
ZIP/Postal Code
060-0063
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Fukuoka
ZIP/Postal Code
814-0180
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Fukushima
ZIP/Postal Code
960-1295
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Gifu
ZIP/Postal Code
501-1194
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Hamamatsu
ZIP/Postal Code
431-3192
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Hyōgo
ZIP/Postal Code
663-8186
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Hyōgo
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Ichinomiya
ZIP/Postal Code
491-8558
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Kagoshima
ZIP/Postal Code
890-8520
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Kyoto
ZIP/Postal Code
602-8566
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Morioka City
ZIP/Postal Code
020-0066
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Nagoya-shi
ZIP/Postal Code
457-8510
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Obihiro
ZIP/Postal Code
080-0013
Country
Japan
Facility Name
LEO Pharma Investigational Site 2
City
Osaka
ZIP/Postal Code
532-0003
Country
Japan
Facility Name
LEO Pharma Investigational Site 1
City
Osaka
ZIP/Postal Code
553-0003
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Osaka
ZIP/Postal Code
583-8588
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Osaka
ZIP/Postal Code
593-8324
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Shimotsuke-shi
ZIP/Postal Code
329-0498
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Tokyo
ZIP/Postal Code
105-8471
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Tokyo
ZIP/Postal Code
113-8603
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Tokyo
ZIP/Postal Code
167-0035
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Toyama
ZIP/Postal Code
933-0871
Country
Japan
Facility Name
LEO Pharma Investigational Site
City
Białystok
ZIP/Postal Code
15-375
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Bochnia
ZIP/Postal Code
32-700
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Bydgoszcz
ZIP/Postal Code
85-094
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Gdańsk
ZIP/Postal Code
80-546
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Gdynia
ZIP/Postal Code
81-338
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Gdynia
ZIP/Postal Code
81-537
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Katowice
ZIP/Postal Code
40-040
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
30-033
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
30-149
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
30-510
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
31-011
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
31-147
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
31-501
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Kraków
ZIP/Postal Code
31-559
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Lublin
ZIP/Postal Code
20-081
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Lublin
ZIP/Postal Code
20-406
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Poznań
ZIP/Postal Code
60-369
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Poznań
ZIP/Postal Code
60-702
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Rzeszów
ZIP/Postal Code
35-055
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Rzeszów
ZIP/Postal Code
35-612
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Warszawa
ZIP/Postal Code
01-141
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Warszawa
ZIP/Postal Code
01-817
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Warszawa
ZIP/Postal Code
02-625
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Warszawa
ZIP/Postal Code
02-953
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Wrocław
ZIP/Postal Code
51-318
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Wrocław
ZIP/Postal Code
51-685
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Wrocław
ZIP/Postal Code
52-416
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Łódź
ZIP/Postal Code
90-242
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Łódź
ZIP/Postal Code
90-265
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Łódź
ZIP/Postal Code
90-436
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Łódź
ZIP/Postal Code
90-752
Country
Poland
Facility Name
LEO Pharma Investigational Site
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Badalona
ZIP/Postal Code
08915
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Barakaldo
ZIP/Postal Code
48903
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Bilbao
ZIP/Postal Code
48013
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Cordoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Fuenlabrada
ZIP/Postal Code
28942
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Granada
ZIP/Postal Code
18014
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
L'Hospitalet De Llobregat
ZIP/Postal Code
08907
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Madrid
ZIP/Postal Code
28031
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Madrid
ZIP/Postal Code
28922
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Pontevedra
ZIP/Postal Code
36003
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Sevilla
ZIP/Postal Code
41007
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
LEO Pharma Investigational Site
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Cottingham
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Dudley
ZIP/Postal Code
DY1 2HQ
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Dundee
ZIP/Postal Code
DD1 9SY
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Harlow
ZIP/Postal Code
CM20 1QX
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Harrogate
ZIP/Postal Code
HG2 7SX
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Leytonstone
ZIP/Postal Code
E11 1NR
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
London
ZIP/Postal Code
N19 5NF
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Redhill
ZIP/Postal Code
RH1 5RH
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Salford
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Sheffield
ZIP/Postal Code
S10 2RX
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Wakefield
ZIP/Postal Code
WF1 4DG
Country
United Kingdom
Facility Name
LEO Pharma Investigational Site
City
Walsall
ZIP/Postal Code
WS2 9PS
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified IPD can be made available to researchers in a closed environment for a specified period of time.
IPD Sharing Time Frame
Data is available to request after results of the trial are available on leopharmatrials.com
IPD Sharing Access Criteria
Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.
IPD Sharing URL
http://leopharmatrials.com/for-professionals
Citations:
PubMed Identifier
35863467
Citation
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink AE, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren RB, Simpson E, Reich K. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19.
Results Reference
derived

Learn more about this trial

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

We'll reach out to this number within 24 hrs